Loading...
Loading...
ALPN| Name | Value |
|---|---|
| Revenues | 2.8M |
| Cost of Revenue | 0.0M |
| Gross Profit | 2.8M |
| Operating Expense | 23.1M |
| Operating I/L | -20.4M |
| Other Income/Expense | 2.1M |
| Interest Income | 2.2M |
| Pretax | -18.3M |
| Income Tax Expense | 0.5M |
| Net Income/Loss | -18.9M |
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company specializing in protein-based immunotherapies for cancer, autoimmune/inflammatory disorders, and other diseases. The company's product pipeline includes ALPN-101, an ICOS/CD28 antagonist program for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for cancer treatment; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune diseases.
